Company: NCEL
Filing Date: 2025-03-10
Form Type: 425
Source: 0001213900-25-021979
Chunk: 7

Company: NewcelX Ltd.
Filing Date: 2025-03-10
Form: 425
Chunk 7
---
15, 2024. Other information regarding the participants in the proxy
solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy
statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when such materials become available.
Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions.
You may obtain free copies of these documents from NLS Pharmaceutics using the sources indicated above.

NLS Contacts:

InvestorRelations@nls-pharma.com

www.nlspharma.com

Kadimastem Contact:

Sarah Bazak, Investors
relations

s.bazak@kadimastem.com

www.kadimastem.com

<div align='center'>5</div>